Status: Recruiting
Inhaled Ciclesonide Study in Preterm Infants
Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
Participants needed: 30
Trial details
Phase: Phase 1Age: 8-35Biological sex: AllType: InterventionalSponsor: Venkatesh SampathUpdated: Mar 27, 2026Locations: 1
Eligibility criteria
Viable Infants born between 23 0/7 - 29 6/7 gestation [+4]
Infants with major congenital lung or other organ anomalies, life-threatening il... [+7]